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shown that ALDH1 positive cells had significantly lower Ki-67
positivity than ALDH1 negative cells (p<0,001). ALDH1 positive
cells never have proliferative level more than 10%.
Nowadays development of metastases often relates to interac-
tion between chemokines and their receptors. In our study we
analyze two receptors: CCR10 and CXCR4 as most known in
literature data.
Investigation of CCR10 and CXCR4 shows, that 77% of colon
cancers have expression of CXCR4 and no one – CCR10. It was
found that low level of proliferation (Ki-67<30%) and expression
of CXCR4 were more often revealed in disseminated cancer (IV
stage) than in localized (II stage), p=0.002. The 5-year relapse- free
survival rate in patients with Ki- 67>70% and CXCR4<30% was
75% and 25%, respectively, with median survival time of 16.5
months. Vice versa cases with CXCR4>70% and Ki-67<30% hadthe
5- year relapse-free survival rates of 32% and in 68%, respectively,
with the median survival time of 7 month. IHC study of MSH2,
MSH6, PMS2, MLH1 shows that at least lack of one marker always
accompanies by microsatellite instability. Mutations of these
markers were accompanied by lack of expression in 100% of
cases. Thus, according to modern classification of colon cancer
grade, we divided 45 cases into low and high grades using only
histological criteria and additionally – IHC investigation of
MSH2, MSH6, PMS2, MLH1. It was shown that in 9% of cases
IHC of these markers prevent incorrect evaluation of cancer
grade. Conclusion: immunohistochemical investigation of CXCR4,
Ki-67, MSH2, MSH6, PMS2, MLH1 may be additional useful prog-
nostic factors for patients with colon adenocarcinoma.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.083
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Melanoma is defined as heterogeneous and complex neoplas-
tic system. Melanoma tumor microenvironment composes of
different cell types including tumor-associated lymphocytes,
macrophages, fibroblasts, etc. These cells may intensify tumor
growth and progression by releasing various active substances.
MicroRNAs are a class of posttranscriptional regulators, which
play an essential role in proliferation, adhesion, motility and
migration of cancer cells. Several studies showed that microRNAs
produced by tumor microenvironment cells could act as
paracrine modulators for modification of cancer cells biological
behavior. For identification of melanoma microenvironment
microRNA profile we performedmicroarray analysis of melanoma
samples (n = 10) obtained from Krasnoyarsk Territory Oncological
Center and macrodissected to separate tumor complexes and
tumor microenvironment.
RNA was extracted from tissue samples by MirVana kit
(Ambion, Life Technologies, Canada) in accordance to manufac-
turer recommendations. The microRNA concentration was
measured by Qubit 2.0 Fluorimeter (Life technologies Holdings
Pte Ltd., USA). miRNA expression profiles were processed by the
Affimetrix microarray system (Affymetrix, Santa Clara, CA,
USA). Expression changes between melanoma and nevi samples
were identified using P-value of 0,05. 2.0-fold difference in either
direction was a minimal fold change expression required. A hier-
archical clustering analysis for differentially expressed miRNAs
was carried out by Transcriptome Analysis Console 2.0.
24 microRNAs were identified with altered expression levels in
melanoma cells as compared to tumor microenvironment cells
including hsa-miR-106a-5p, hsa-miR-3178, hsa-miR-223-3p,
hsa-miR-17-5p, hsa-miR-221-3p, hsa-miR-4745-5p, hsa-miR-107,
hsa-miR-363-3p, hsa-miR-4739, hsa-miR-514b-5p, hsa-miR-3175,
hsa-miR-6805-5p, hsa-miR-6769b-5p. Of 24 miRNAs, 3 were
upregulated in melanoma microenvironment as compared to
melanoma cells, whereas 21 were downregulated. Among these
microRNA, miR-106a-5p was the most downregulated in microen-
vironment, while miR-4433b-5p was found to be the most upreg-
ulated. Of the 24 differentially expressed miRNAs in the tumor
microenvironment, DIANA-miR-path identified 9 miRNAs with
predicted gene targets. MiR-106a-5p as the most upregulated in
melanoma tissue was identified to be involved in MAPK,
TGF-beta signaling pathways regulation. Besides, miR-106a-5p
participates in actin cytoskeleton regulation, adherens junction
and focal adhesion that may correspond to increased motility of
melanoma cells.
MicroRNA profiling may serve as useful tool for preliminary
microRNA search with following their target genes identification
for investigation of epigenetic regulation mechanisms in cancer.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.084
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Background: Glioblastomas (GBL) are most aggressive brain
tumors in adults. They are often radio- and chemotherapy resis-
tant. The standard therapy of GBL includes surgery followed by
radiotherapy with concomitant chemotherapy with temozolo-
mide named temodal (imidazotetrazine derivative). Methylation
of the O6-methylguanine-DNA-methyltransferase (MGMT) gene
promoter is considered as predictor of better outcome of temodal
therapy in comparison with the cases without MGMT promoter
methylation (Stupp et al., 2009). The aim of this study is finding
of additional predictors of temozolomide therapy effectiveness.
Materials and methods: We obtained primary cultures of GBL.
The rate of GBL sensitivity to temozolomide was revealed by
MTT test. Expression of multidrug resistance genes and genes
which mediate temozolomide sensitivity (YB1, MDR1, MRP1,
LRP, BCRP and MGMT) was determined by real time PCR. Protein
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